Application of MUCIN-16 and other biomarkers, including WFDC2 (WAP Four-Disulfide Core Domain 2, also known as HE4—human epididymal protein 4), such as in the ROMA Score (Ovarian Malignancy Risk Algorithm), can increase the sensitivity to 94.8% at a specificity of 75%8 in patient cohorts with predominantly (74.6%) late stage (III and IV) ovarian cancers. This evidence concerns the gene WFDC2 and ovarian carcinoma.